[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sakuragawa et al., 1975 - Google Patents

Significance of a prothrombin assay method using Echis carinatus venom for diagnostic information in disseminated intravascular coagulation syndrome

Sakuragawa et al., 1975

Document ID
4076998584197987247
Author
Sakuragawa N
Takahashi K
Hoshiyama M
Jimbo C
Matsuoka M
Onishi Y
Publication year
Publication venue
Thrombosis Research

External Links

Snippet

Prethrombin 1 was found in the blood of patients who have the disseminated intravascular coagulation syndrome (DIC). Prothrombin assay method using Echis carinatus venom is useful for detecting prothrombin derivatives such as prethrombin 1 (1) in DIC. This …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Similar Documents

Publication Publication Date Title
Ratnoff et al. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI)
Colucci et al. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
Rand et al. Coagulation defects in acute promyelocytic leukemia
Niemetz et al. Activated coagulation factors: in‐vivo and in‐vitro studies
RATNOFF et al. Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome
Levin et al. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.
McNicol et al. In-vitro and in-vivo studies of a preparation of urokinase
Stecher et al. The chemotactic activity of fibrin lysis products
Lorand et al. Assay method for the “fibrin-stabilizing factor.”
Clark et al. Effects of recombinant erythropoietin on murine megakaryocytic colony formation in vitro
Shafer et al. Monitoring activity of fibrinolytic agents: a therapeutic challenge
Thompson et al. Removal of heparin and protamine from plasma
Giles et al. Studies of factors V and VIII: C in an animal model of disseminated intravascular coagulation.
Dubber et al. In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor
Sakuragawa et al. Significance of a prothrombin assay method using Echis carinatus venom for diagnostic information in disseminated intravascular coagulation syndrome
Niemetz The role of protein synthesis on the generation of tissue factor activity by leukocytes
Martinez et al. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states
Eichinger et al. Determinants of plasma factor VIIa levels in humans
Handley et al. A circulating anticoagulant specific for factor V
Deutsch et al. Blood coagulation changes under L-asparaginase therapy
JP3198111B2 (en) Method for measuring hirudin and synthetic thrombin inhibitor
Lewis et al. Effects of Epsilon Aminocaproic Acid on Coagulation and Fibrinolytic Mechanisms: Studies of epsilon aminocaproic acid therapy in cirrhotic patients without gross bleeding tendencies suggest that the low factor V levels found in liver disease are caused by decreased production, not by increased destruction
Ferguson et al. Enzymes and blood clotting. I. Trypsin as an accessory factor
Wilson et al. Effect of fibrinogen degradation products on platelet aggregation
Guest et al. A study of the antifibrinolysin activity in human plasmas during pathological states